Drug Discovery@nature.com 21 October 2011

TABLE OF CONTENTS 21 October 2011 News Analysis Research Highlights Research & Reviews Careers Nature Reviews Drug Discovery is on Twitter Advertisement Miami 2012 Winter Symposium: Nanotechnology in Biomedicine February 26-29, 2012 • Miami, FL, USA The 45th Miami Winter Symposium will bring together leaders in the field to discuss breakthroughs in new nanomaterials and the challenges in translating these materials into products for the clinic and laboratory. For more information and to register, visit: www.nature.com/natureconferences/miami/mws2012?WT.mc_id=NC1108TK010   News Top Seattle Genetics rare cancer drug sails through accelerated approval doi:10.1038/nbt1011-851 Seattle Genetics has received approval from the US Food and Drug Administration for its immunoconjugate drug Adcetris (brentuximab vedotin) for relapsing Hodgkin's lymphoma and anaplastic large cell lymphoma. Full Text HIV drugs made in tobacco doi:10.1038/nbt1011-852 UK regulators have approved Pharma-Planta's phase-1 clinical trial to test an anti-HIV type 1 protein human monoclonal antibody made in genetically modified tobacco plants to stop transmission of the virus between sexual partners. Full Text Engineered T-cell therapy shows efficacy in blood cancer doi:10.1038/nbt1011-853 Two out of three patients with advanced chronic lymphocytic leukemia treated with engineered T cells showed complete remission in a pilot study, although concerns about manufacturing, reimbursement and potential autoimmune complications might hinder the path to market. Full Text Trial watch: Apixaban beats warfarin in stroke trial doi:10.1038/nrd3593 In clinical trials, the novel oral anticoagulant apixaban, which inhibits factor Xa, was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding and resulted in a lower mortality rate in patients with atrial fibrillation. Full Text Analysis Top Going antiviral in brain cancer doi:10.1038/scibx.2011.1104 Findings that targeting cytomegalovirus and/or inhibiting cyclooxygenase-2 could help treat medulloblastoma might lead to repurposing opportunities for companies with compounds against the virus or the enzyme. Full Text Ezogabine (retigabine) doi:10.1038/nrd3561 Ezogabine, a potassium channel opener, was approved in June 2011 by the US Food and Drug Administration for the adjunctive treatment of partial-onset seizures in adult patients. The same drug was granted marketing authorization for this indication in the European Union in March 2011, where it is known as retigabine. Full Text Antibacterial R&D incentives doi:10.1038/nrd3560 This article outlines the objectives of incentives for antibacterial R&D and compares the ability of various incentive policies to address the long-term challenge of antibacterial resistance. Full Text Research Highlights Top Antivirals: New clues for flu vaccine design doi:10.1038/nrd3567 Human monoclonal antibodies exhibiting broad neutralizing activity against type A influenza viruses have been identified. Full Text Synthetic biology: Licensing bacteria to kill doi:10.1038/nrmicro2660 Reports on the design and testing of an engineered Escherichia coli strain that specifically targets Pseudomonas aeruginosa. Full Text Immunotherapy: Leukadherins get a grip on inflammation doi:10.1038/nri3079 New drugs promoting integrin activation prevent inflammatory cells from being recruited to inflamed tissues. Full Text Research & Reviews Top The influence of the 'organizational factor' on compound quality in drug discovery doi:10.1038/nrd3552 The results of an in-depth comparison of patented compounds from different companies acting on the same targets indicates the continued production of compounds with suboptimal physiochemical profiles. Full Text Development of subtype-selective oestrogen receptor-based therapeutics doi:10.1038/nrd3551 This article outlines the roles of oestrogen receptor α and oestrogen receptor β in various animal disease models, and details how agonists that selectively target either receptor subtype might provide a more efficacious therapy than targeting both for certain diseases. Full Text The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension doi:10.1038/nm.2497 This article describes how thiazide diuretics could be used to prevent hypertension mediated by activation of the renal sodium chloride cotransporter that is associated with the use of calcineurin inhibitor immunosuppressants. Full Text Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia doi:10.1038/nature10509 In this study, a novel small molecule inhibitor of the BET family has been shown to displace BET proteins from chromatin to induce early cell cycle arrest and apoptosis in MLL-fusion leukaemic cell lines and to provide survival benefit in two mouse models of leukaemia. Full Text Drug Discovery JOBS of the week Professor in Cellular Signaling Network Biology Technical University of Denmark, Department of Systems Biology (CBS) DK Postdoctoral Researcher / Senior Postdoctoral Researcher Louisiana State University Baton Rouge, US Associate Professor in Computational Biology / Bioinformatics University of Fribourg Fribourg, CH Graduate Program The Leipzig School of Human Origins Leipzig, DE Graduate Program The Leipzig School of Human Origins Leipzig, DE More Science jobs from Drug Discovery EVENT Project Management for Phase 1 & 2 Clinical Trials 31.10.-01.11.11 PA, US More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Advertisement SciBX: Science-Business eXchange is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Recommend SciBX to your library today.   Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.